Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate-grade and high-grade non-Hodgkin's lymphoma in first complete remission: a study of 464 patients. Groupe d'Etude des Lymphomes de l'Adulte.

Haı̈oun, Corinne; Lepage, Éric; Gisselbrecht, Christian; Coiffier, B; Bosly, André; Tilly, Hervé; Morel, Pierre; Nouvel, C.; Herbrecht, Raoul; d'Agay, MF

doi:10.1200/jco.1994.12.12.2543

Cited by 181 publications

(50 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For these patients, more intensive regimens should be tested 18 or high-dose therapy with autologous stemcell transplantation. 15,19 In conclusions, PCLL behave like other localized B or T large-cell extranodal lymphomas with the same prognostic factors (LDH level, ECOG score, age), except for CD30 + PCLL which have a better prognosis than nodal CD30 + malignant lymphomas. 20 Treatment should be tailored according to immunohistology and extent of the cutaneous disease.…”

Section: Discussionmentioning

confidence: 85%

“…One patient recieved late intensification with highdose therapy (CBV) and autologous bone marrow transplantation. 15 No adjustment was made for hematological toxicity, but chemotherapy was delayed until the neutrophil count was above 1000 × 10 9 /l and platelet count above 100 000 × 10 9 /l. No radiation therapy was recommended in the protocol, but 2/49 patients received radiotherapy to localized cutaneous lesions.…”

Section: Treatmentmentioning

confidence: 99%

See 1 more Smart Citation

Primary cutaneous large-cell lymphoma: analysis of 49 patients included in the LNH87 prospective trial of polychemotherapy for high-grade lymphomas

et al. 1998

Self Cite

View full text Add to dashboard Cite

The objectives of this study were to evaluate the outcome after polychemotherapy for patients with primary cutaneous largecell lymphomas (PCLL) and to validate the recently proposed immunohistologic classification of cutaneous lymphomas. Among 140 patients with positive skin biopsies included in the LNH87 protocol (for treatment of aggressive lymphomas), 49 patients met the criteria of PCLL. Characteristics were: sex ratio M/F, 2.3; age 18 to 83 years (median, 52), peripheral lymph nodes, n = 22; diffuse disease, n = 12; median tumor size, 4.5 cm; elevated lactate dehydrogenase, n = 9; ECOG: 0/1, n = 49. Histology was: follicular center B cell, n = 23; B-lymphoblastic, n = 1; anaplastic large-cell lymphoma, n = 14 (T cell phenotype n = 8); CD30 ؊ T cell lymphoma, n = 11. All patients received polychemotherapy: under 70 years, ACVBP (three to four cycles and consolidation for 6 months) n = 25; mBACOD (eight cycles) n = 16; over 70 years, C(T)VP (six cycles) n = 8. Radiation therapy was not included in the protocol. With a median follow-up of 5 years, 24/49 patients had relapsed, with 20 skin relapses. Event-free (EFS) and overall survival (OS) at 5 years were, respectively, 50 and 77%. Significant adverse prognostic factors were: histology (CD30 ؊ T cell lymphoma) and diffuse cutaneous disease (Ͼ Ͼ Ͼ10% of skin). The presence of nodal involvement was only significant for EFS. When compared to 140 non-cutaneous lymphoma patients included in the same trial and fully matched for the main clinical characteristics, OS was similar. In conclusion, PCLL behaves like other localized B or T cell extranodal lymphomas with the same prognostic factors (LDH, ECOG, age) except for CD30 ؉ PCLL which have a very good prognosis.

show abstract

Section: Discussionmentioning

confidence: 85%

Section: Treatmentmentioning

confidence: 99%

Primary cutaneous large-cell lymphoma: analysis of 49 patients included in the LNH87 prospective trial of polychemotherapy for high-grade lymphomas

et al. 1998

Self Cite

View full text Add to dashboard Cite

show abstract

“…A clinical improvement was observed after the first course of NCVBP chemotherapy (mitoxantrone 12 mg/m 2 day 1, cyclophosphamide 1200 mg/m 2 day 1, vinblastine 2 mg/m 2 days 1 and 5, bleomycine 10 mg days 1 and 5, prednisone 60 mg/m 2 from day 1 to day 5, intrathecal methotrexate 12 mg day 1). 20 Despite CNS prophylaxis, a meningeal relapse occurred after the third course. The patient received salvage chemotherapy with IVAM regimen (ifosfamide 1500 mg/m 2 daily for 5 days + mesna, etoposide 150 mg/m 2 daily for 3 days, cytarabine 100 mg/m 2 daily for 3 days, methotrexate 3 g/m 2 at day 5 with leucovorin rescue) 21 followed by an autologous peripheral blood stem cell transplantation.…”

Section: Figurementioning

confidence: 99%

De novo acute B cell leukemia/lymphoma with t(14;18)

Stamatoullas¹,

Buchonnet

Leprêtre³

et al. 2000

Leukemia

Self Cite

View full text Add to dashboard Cite

The t(14;18)(q32;q21) translocation is the most common translocation in B cell malignancies being found in 80% of follicular lymphomas and about 20% of diffuse large B cell lymphomas. Only rare cases of de novo acute B cell lymphoblastic leukemia with t(14;18) have been described. We describe five cases of this entity which appears to have very homogeneous clinical, phenotypic and genotypic features. None of these patients had prior history of follicular lymphoma. The disease was characterized by acute clinical features with nodal and/or extranodal disease, massive bone marrow infiltration and rapid increase of circulating blast cells of mature B cell phenotype. All patients disclosed complex chromosomal and molecular abnormalities involving at least the BCL-2 and c-MYC genes. Furthermore, three patients had evidence of BCL-6 involvement and one patient had a p53 mutation. Despite intensive chemotherapy, including for two patients allogeneic bone marrow transplantation in first complete remission, all patients died within a few months. Neuro-meningeal relapse occurred in three of the five patients in spite of neuro-meningeal prophylaxis. De novo leukemia/lymphoma with t(14;18) is a rare entity with a very poor prognosis. Whether early bone marrow transplant could modify the natural history of the disease remains to be determined. An intensive neuro-meningeal prophylaxis appears to be mandatory in these patients. Leukemia (2000Leukemia ( ) 14, 1960Leukemia ( -1966

show abstract

“…53 However, this trial was instituted before the publication of the IPI, and treatment-related differences became apparent when study patients were retrospectively grouped into risk groups according to the age-adjusted IPI. In the retrospective analysis, 451 patients were determined to be high-intermediateor high-risk IPI patients (two risk factors, n ¼ 318; three risk factors, n ¼ 133), and 277 (61%) achieved CR and were eligible for the randomization to HDT or chemotherapy.…”

Section: Treatment With Hdtmentioning

confidence: 99%

“…In the majority of these trials, poor-risk disease was identified by criteria other than the IPI or age-adjusted IPI. Various paradigms for upfront HDT were investigated, namely, following a CR after a full course of induction therapy; 53,55 following a full course of induction therapy, regardless of response; 57 following a CR or PR 58 or 'minor' response 60 after abbreviated standard-dose chemotherapy or abbreviated dose-intense chemotherapy; 56,59,61 and following a 'slow' response to induction chemotherapy 54 (Table 5 and 6). …”

Section: Treatment With Hdtmentioning

confidence: 99%

Current trends in large cell lymphoma

Fisher

Shah

2003

Leukemia

View full text Add to dashboard Cite

For the last decade, cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) has been the best available standard of care for aggressive non-Hodgkin's lymphoma (NHL), based on equivalent therapeutic results with other multiagent chemotherapy accompanied by lower costs and lesser toxicity. However, only 40-45% of these patients are cured with CHOP. New treatment strategies have been employed, including the addition of Rituximab to CHOP in elderly patients; dose escalation using granulocyte-colony-stimulating factor; overcoming the multidrug resistance phenotype with infusional chemotherapeutic regimens and use of some newer agents. Furthermore, the International Prognostic Factor index (IPI) has permitted identification of subsets of patients with large variations in prognosis, allowing prognosis specific therapy to be tested. There is now accumulating evidence that the clinical behavior of certain NHL can be profiled by the expression of certain molecular markers, which will undoubtedly play a role in the development of new prognostic models that may refine our ability to identify poor-risk patients. Regardless, there is still significant opportunity for improving survival in large cell lymphomas.

show abstract

Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate-grade and high-grade non-Hodgkin's lymphoma in first complete remission: a study of 464 patients. Groupe d'Etude des Lymphomes de l'Adulte.

Abstract: For such a subset of patients, consolidation with the CBV regimen followed by autologous bone marrow transplantation is not superior to sequential chemotherapy.

Cited by 181 publications

References 20 publications

Primary cutaneous large-cell lymphoma: analysis of 49 patients included in the LNH87 prospective trial of polychemotherapy for high-grade lymphomas

Primary cutaneous large-cell lymphoma: analysis of 49 patients included in the LNH87 prospective trial of polychemotherapy for high-grade lymphomas

De novo acute B cell leukemia/lymphoma with t(14;18)

Current trends in large cell lymphoma

Contact Info

Product

Resources

About